Appointment of Medicines Australia Board of Directors, Chair and Deputy and Chair
Mr Wes Cook, Managing Director of Boehringer Ingelheim Australia, has been re-elected as the Chair of Medicines Australia with Dr Anna Lavelle re-endorsed as Independent Deputy Chair.
The appointments followed the announcement of the new Board of Medicines Australia at the association’s Annual General Meeting in Sydney today (see list below).
Medicines Australia Chief Executive Mr Milton Catelin said, “Wes has shown outstanding leadership as Chair and helped to guide the strategic direction of our industry for quite some time now, including the Strategic Agreement signed earlier this year with the Commonwealth.”
“As our Deputy Chair and independent Board member, Dr Lavelle provides expertise on Board governance as well as invaluable insights into the broader biopharmaceutical and medical research sector from her years of industry experience.”
“I would like to congratulate all new and returning Medicines Australia Board Members who were selected by their peers following the recently conducted members’ ballot.”
The new Board announced at today’s Annual General Meeting will serve until October 2019.
|Chair||Mr Wes Cook||Managing Director|
Boehringer Ingelheim Pty Ltd
|Independent Director and Deputy Chair||Dr Anna Lavelle|
|Director||Anne Belcher||Vice President/General Manager||GlaxoSmithKline Australia Pty Ltd|
General Manager ANZ
|Shire Australia Pty Limited|
|Director||Michala Fischer- Hansen||VP and General Manager – Oceania||Novo Nordisk Pharmaceuticals Pty Ltd-Australia|
|Director||Bruce Goodwin||Managing Director|
Janssen-Cilag Pty Limited
|Director||James Jones||Managing Director||Takeda Pharmaceuticals Australia Pty Ltd|
|Director||Melissa McGregor||Managing Director||Pfizer Australia Pty Ltd|
|AbbVie Pty Ltd|
|Director||Svend Petersen||Managing Director||Roche Products Pty Limited|
|Managing Director Australia/New Zealand||Bristol-Myers Squibb Australia Pty Ltd|
“On behalf of Medicines Australia, I would like thank all outgoing Board members, for their commitment to the innovative medicines industry during their time as Directors,” said Mr Catelin.
“They deserve enormous gratitude from the sector for their role in developing a Strategic Agreement with the Commonwealth that provides certainty for industry, incredible value for taxpayers and better access for Australians to innovative medicines.”
“The announcement of a new Board is an important milestone for the membership. It provides both continuity as well as fresh leadership that will help to steer the strategic direction of Medicines Australia and the industry more broadly for the years to come.”
“I look forward to working closely with the new Board and once again offer them my congratulations,” said Mr Catelin.
Natalie Wimmer email@example.com Phone: 0450 728 660